ArticleACS nanoscience Au2025
Lipid Nanoparticle Delivery of mRNA and siRNA for Concurrent Restoration of Tumor Suppressor and Inhibition of Tumorigenic Driver in Prostate Cancer.
Article in ACS nanoscience Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanotechnology in Prostate Cancer: PSMA-Targeted Nanoplatforms, TME-Responsive Therapy, Immunomodulation, and Clinical Translation Challenges.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer is commonly caused by a gain of function in proto-oncogenes and a simultaneous loss of function in tumor suppressor genes. Advanced prostate cancer (PCa) is often linked with changes in the activity or expression of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a well-known tumor suppressor, and androgen receptor (AR), a pro-tumorigenic transcription factor. However, no therapies exist for the simultaneous correction of tumorigenic promotion and suppressor depletion. Here, we report that concurrent PTEN restoration and AR silencing by lipid nanoparticle (LNP) delivery of PTEN messenger RNA (mPTEN) and AR small interfering RNA (siAR) elicited synergistic therapeutic effects in PCa cells. We screened various LNP formulations for the optimal delivery of both RNAs. In C4-2 and LNCaP cells, both of which are AR-positive and PTEN-null PCa cell lines, the combinatorial treatment of siAR and mPTEN LNPs resulted in much stronger cytotoxicity in vitro than the treatment of either alone. Western blot analyses revealed concurrent regulation of phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) and extracellular signal-regulated kinase (ERK) pathways, leading to increased caspase-3 cleavage-mediated apoptosis. Our findings suggest that the strategy of RNA-mediated concurrent restoration of tumor suppressors and inhibition of tumorigenic drivers could lead to the more effective treatment of PCa and potentially other malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.